Associations between β-amyloid kinetics and the β-amyloid diurnal pattern in the central nervous system

JAMA Neurology

Volumn 74, Issue 2, 2017, Pages 207-215

  Lucey, Brendan P ^a   Mawuenyega, Kwasi G ^a   Patterson, Bruce W ^a   Elbert, Donald L ^b   Ovod, Vitaliy ^a   Kasten, Tom ^a   Morris, John C ^a   Bateman, Randall J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY IN ST LOUIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; LEUCINE; LEUCINE C 13; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); CARBON; PEPTIDE FRAGMENT;

ADULT; AGE; AGED; ARTICLE; CENTRAL NERVOUS SYSTEM; CIRCADIAN RHYTHM; CLEARANCE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IN VIVO STUDY; INDWELLING CATHETER; INDWELLING LUMBAR CATHETER; INTERMETHOD COMPARISON; ISOTOPE LABELING; KINETICS; MALE; MASS SPECTROMETRY; MISSOURI; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN SYNTHESIS; SLEEP WAKING CYCLE; TURNOVER TIME; VALIDATION STUDY; VOLUNTEER; CEREBROSPINAL FLUID; DIAGNOSTIC IMAGING; GERIATRIC ASSESSMENT; METABOLISM; MIDDLE AGED; PHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; STATISTICS; TIME FACTOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AMYLOID BETA-PEPTIDES; CARBON RADIOISOTOPES; CENTRAL NERVOUS SYSTEM; CIRCADIAN RHYTHM; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GERIATRIC ASSESSMENT; HUMANS; KINETICS; LEUCINE; MALE; MASS SPECTROMETRY; MIDDLE AGED; PEPTIDE FRAGMENTS; POSITRON-EMISSION TOMOGRAPHY; STATISTICS AS TOPIC; TIME FACTORS;

EID: 85014728237     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2016.4202     Document Type: Article

References (26)

1. Prince M, Wimo A, GuerchetM, Ali G-C, Wu Y-T, Prina M.World Alzheimer Report 2015: The Global Impact of Dementia: An Analysis of Prevalence. London, England: Alzheimer's Disease International; 2015.
2. Patterson BW, Elbert DL, Mawuenyega KG, et al. Age and amyloid effects on human central nervous system amyloid-beta kinetics. Ann Neurol. 2015; 78(3):439-453.
3. Meyer-Luehmann M, Stalder M, Herzig MC, et al. Extracellular amyloid formation and associated pathology in neural grafts. Nat Neurosci. 2003;6(4): 370-377.
4. Kang J-E, Lim MM, Bateman RJ, et al. Amyloid-β dynamics are regulated by orexin and the sleep-wake cycle. Science. 2009;326(5955):1005-1007.
5. Huang Y, Potter R, SigurdsonW, et al. Effects of age and amyloid deposition on Aβ dynamics in the human central nervous system. Arch Neurol. 2012;69(1):51-58.
6. Roh JH, Huang Y, Bero AW, et al. Disruption of the sleep-wake cycle and diurnal fluctuation of β-amyloid in mice with Alzheimer's disease pathology. Sci Transl Med. 2012;4(150):150ra122.
7. Lucey BP, Gonzales C, Das U, et al. An integrated multi-study analysis of intra-subject variability in cerebrospinal fluid amyloid-β concentrations collected by lumbar puncture and indwelling lumbar catheter. Alzheimers Res Ther. 2015;7(1):53.
8. Lucey BP, Bateman RJ. Amyloid-β diurnal pattern: Possible role of sleep in Alzheimer's disease pathogenesis. Neurobiol Aging. 2014;35(suppl 2):S29-S34.
9. Xie L, Kang H, Xu Q, et al. Sleep drives metabolite clearance from the adult brain. Science. 2013;342(6156):373-377.
10. Kress BT, Iliff JJ, Xia M, et al. Impairment of paravascular clearance pathways in the aging brain. Ann Neurol. 2014;76(6):845-861.
11. Morris JC. The Clinical Dementia Rating (CDR): Current version and scoring rules. Neurology. 1993; 43(11):2412-2414.
12. Berg L, Miller JP, Storandt M, et al. Mild senile dementia of the Alzheimer type 2: Longitudinal assessment. Ann Neurol. 1988;23(5):477-484.
13. Mintun MA, Larossa GN, Sheline YI, et al. [11C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease. Neurology. 2006;67(3):446-452.
14. Mawuenyega KG, Kasten T, Ovod V, Lucey B, SigurdsonW, Bateman RJ. Immuno-based-LC/SRM as a diagnostic tool for protein dynamics of amyloid β isoforms instead of ELISA in the clinical laboratory. Paper presented at: 62nd Conference on Mass Spectrometry and Allied Topics; June 15-19, 2014; Baltimore, MD.
15. Bateman RJ, Munsell LY, Morris JC, Swarm R, Yarasheski KE, Holtzman DM. Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med. 2006;12(7): 856-861.
16. Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol. 2006;59(3):512-519.
17. Potter R, Patterson BW, Elbert DL, et al. Increased in vivo amyloid-β42 production, exchange, and loss in presenilin mutation carriers. Sci Transl Med. 2013;5(189):189ra77.
18. Elbert DL, Patterson BW, Bateman RJ. Analysis of a compartmental model of amyloid beta production, irreversible loss and exchange in humans. Math Biosci. 2015;261:48-61.
19. Vlassenko AG, McCue L, Jasielec MS, et al. Imaging and cerebrospinal fluid biomarkers in early preclinical alzheimer disease. Ann Neurol. 2016;80 (3):379-387.
20. Bateman RJ, Wen G, Morris JC, Holtzman DM. Fluctuations of CSF amyloid-β levels: Implications for a diagnostic and therapeutic biomarker. Neurology. 2007;68(9):666-669.
21. Li J, Llano DA, Ellis T, et al. Effect of human cerebrospinal fluid sampling frequency on amyloid-β levels. Alzheimers Dement. 2012;8(4): 295-303.
22. Moghekar A, Goh J, Li M, AlbertM, O'Brien RJ. Cerebrospinal fluid Aβ and tau level fluctuation in an older clinical cohort. Arch Neurol. 2012;69(2): 246-250.
23. Slats D, Claassen JA, Spies PE, et al. Hourly variability of cerebrospinal fluid biomarkers in Alzheimer's disease subjects and healthy older volunteers. Neurobiol Aging. 2012;33(4):831.e1-831.e9.
24. Dobrowolska JA, Kasten T, Huang Y, et al. Diurnal patterns of soluble amyloid precursor protein metabolites in the human central nervous system. PLoS One. 2014;9(3):e89998.
25. Ooms S, Overeem S, Besse K, RikkertMO, Verbeek M, Claassen JA. Effect of 1 night of total sleep deprivation on cerebrospinal fluid β-amyloid 42 in healthy middle-aged men: A randomized clinical trial. JAMA Neurol. 2014;71(8):971-977.
26. Van Broeck B, Timmers M, Ramael S, et al. Impact of frequent cerebrospinal fluid sampling on Aβ levels: Systematic approach to elucidate influencing factors. Alzheimers Res Ther. 2016;8(1): 21.